Vid Curasights årsstämma godkände aktieägarna styrelsens rapport om företagets verksamhet under 2025. Årsredovisningen för 2025 antogs enhälligt, och beslutades att resultatet för året skulle föras vidare till nästa år. Kirsten Aarup Drejer, Andreas Kjær och Ulrich Krasilnikoff omvaldes till styrelsen, medan Marcel Reichen och Colin Hayward valdes in som nya medlemmar, vilket ersatte Lars Trolle och Charlotte Vedel. PricewaterhouseCoopers omvaldes som företagets revisor. Inga nya förslag från styrelsen eller aktieägarna lades fram. Efter stämman omvaldes Kirsten Drejer som styrelseordförande och Andreas Kjær valdes till vice ordförande.

The agenda for Curasight A/S's Annual General Meeting includes the Board of Directors’ report on the company's activities in the past financial year, presentation and approval of the annual report, and decisions on profit appropriation or loss coverage as per the annual report. Elections for the Board of Directors and an auditor are also on the agenda, with proposals for re-election of certain board members and the introduction of new candidates due to resignations. PricewaterhouseCoopers is proposed for re-election as auditor. Shareholders can submit resolutions and participate in voting, which requires a simple majority. Details about share capital, voting rights, and procedures for attending or voting by proxy or postal vote are provided. The meeting will be conducted in Danish, and personal data of shareholders is processed in line with legal requirements. Curasight is focused on developing uTREAT®, a therapy targeting uPAR in solid tumors, and uTRACE®, an imaging agent for patient selection. More information is available on their website.

Curasight has increased its number of ordinary shares by 429,363 following a conversion, raising the total from 47,922,841 to 48,352,204 shares. This results in a share capital increase from DKK 2,396,142.05 to DKK 2,417,610.20, causing a dilution effect of about 0.9%. Curasight's CEO, Ulrich Krasilnikoff, views Fenja Capital's decision to convert debt into shares positively, as it reduces debt and extends the company's financial runway. Fenja Capital sold all converted shares in a block transaction to a group of long-term investors at DKK 15.75 per share, totaling approximately DKK 6.8 million, representing a 0.9% discount to the closing price on the Spotlight Stock Market. Curasight is developing uTREAT®, a radioligand therapy for solid tumors, and uTRACE®, a PET imaging agent, both targeting uPAR, a key factor in tumor progression. The uPAR platform is based on research from Copenhagen University Hospital and the University of Copenhagen. Sedermera Corporate Finance AB served as the sole bookrunner for the placement.

Curasight's CEO, Ulrich Krasilnikoff, highlighted 2025 as a transformative year for the company, transitioning to a clinical-stage radiopharmaceutical company. The company dosed its first patient in a Phase 1 glioblastoma trial and advanced its Phase 2 trial in prostate cancer. Curasight aims to focus on clinical execution, data generation, and strategic decisions in 2026, supported by a strengthened financial position. Financially, Curasight reported a gross loss of kDKK -49,676, an operating loss of kDKK -55,592, and a loss before tax of kDKK -58,730 for 2025. The loss for the year was kDKK -53,230, with total assets of kDKK 50,055 and an equity ratio of 37.1%. Earnings per share were DKK -1.1. Comparisons are made with 2024 figures in parentheses.

Curasight's CEO, Ulrich Krasilnikoff, reported that the company made significant progress in Q4 2025 by advancing to a clinical-stage therapeutic company with its uTREAT® platform, targeting uPAR across various tumor types. The uTREAT® platform, supported by the uTRACE® diagnostic platform, began its Phase 1 trial in glioblastoma, with results expected in 2026. The uTRACE® platform is also progressing in a Phase 2 prostate cancer trial, with top-line data anticipated in 2026. Financially, Curasight ended 2025 with DKK 63.4 million in cash and DKK 40 million in new and renegotiated debt facilities. Key financial figures for Q4 2025 include a gross loss of kDKK -14,577, operating loss of kDKK -16,203, and a loss before tax of kDKK -16,686. For the full year 2025, the gross loss was kDKK -49,676, operating loss was kDKK -55,592, and loss before tax was kDKK -58,730. Total assets were kDKK 50,055, with an equity ratio of 37.1%, and earnings per share were DKK -1.1. These figures show an increase in losses compared to the previous year.

Curasight will broadcast a live audio webcast online, available in the investor section of their website 48 hours after airing. During the TD Cowen conference, Curasight's management will hold one-on-one meetings with investors and industry stakeholders. This conference is a significant event where healthcare companies engage with institutional investors and large pharmaceutical companies through scheduled meetings and discussions. Curasight A/S is developing uTREAT®, a clinical-stage radioligand therapy targeting uPAR, which is involved in tumor growth and spread, and is present in over 85% of solid tumors. Their platform also includes uTRACE®, a uPAR-PET imaging agent that aids in patient selection and tumor targeting, tested in over 450 patients across various trials. The uPAR platform is based on extensive research from Copenhagen University Hospital and the University of Copenhagen. For more information, contact CEO Ulrich Krasilnikoff via email or visit their website.

Innan transaktionen ägde aktieägaren 5,29% av aktiekapitalet och rösträtterna i företaget. Efter transaktionen innehar aktieägaren nu 4,85%, vilket motsvarar ett ägande under 5%. Detta meddelande publiceras i enlighet med de gällande reglerna för större aktieägaranmälningar på Spotlight Stock Market. För mer information om Curasight, kontakta Ulrich Krasilnikoff, VD, via e-post på uk@curasight.com eller besök www.curasight.com.